Cargando…

Second-line Hormonal Therapy for the Management of Metastatic Castration-resistant Prostate Cancer: a Real-World Data Study Using a Claims Database

We evaluated the efficacy of second-line hormonal therapy for treatment of metastatic castration-resistant prostate cancer (mCRPC) in a real-world retrospective study. We conducted a population-based real-world cohort study of 258 mCRPC patients between 2014 and 2018 using the Chang Gung Research Da...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Jui-Ming, Lin, Cheng-Chia, Liu, Kuan-Lin, Lin, Cheng-Feng, Chen, Bing-Yu, Chen, Tien-Hsing, Sun, Chi-Chin, Wu, Chun-Te
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7060246/ https://www.ncbi.nlm.nih.gov/pubmed/32144327 http://dx.doi.org/10.1038/s41598-020-61235-4

Ejemplares similares

Taiwan Biobank: making cross-database convergence possible in the Big Data era
por: Lin, Jui-Chu, et al.
Publicado: (2017)

High Tumor Burden Predicts Poor Response to Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Patients
por: Hsieh, Yu-Ting, et al.
Publicado: (2021)

Surgical Castration in Hormone-Refractory Metastatic Prostate Cancer Patients Can Be an Alternative for Medical Castration
por: Zaitsu, Masayoshi, et al.
Publicado: (2012)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

Abiraterone for castration-resistant prostate cancer: adherence, survival and hospitalization: Analysis of a medical claims database
por: Mohamad Al-Ali, Badereddin, et al.
Publicado: (2016)

Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database
por: Pal, Sumanta, et al.
Publicado: (2019)

Positive Predictive Value of ICD-10 Codes for Cerebral Venous Sinus Thrombosis in Taiwan’s National Health Insurance Claims Database
por: Liao, Shu-Chen, et al.
Publicado: (2022)

Treatment-Emergent Co-Morbidities and Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide
por: Lin, Yi-Ting, et al.
Publicado: (2021)

Healthcare costs and utilization of diabetes-related complications in Taiwan: A claims database analysis
por: Cheng, Ssu-Wei, et al.
Publicado: (2018)

Treatment-Related Healthcare Costs of Metastatic Castration-Resistant Prostate Cancer in Germany: A Claims Data Study
por: Kreis, Kristine, et al.
Publicado: (2020)

Healthcare Costs in Men with Metastatic Castration-Resistant Prostate Cancer: An Analysis of US Medicare Fee-For-Service Claims
por: Freedland, Stephen J., et al.
Publicado: (2023)

Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer
por: Tseng, Chi-Shin, et al.
Publicado: (2023)

Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer
por: Paller, Channing J, et al.
Publicado: (2011)

The second docetaxel rechallenge for metastatic castration-resistant prostate cancer: a case report
por: Ning, Wei, et al.
Publicado: (2023)

Trend and risk factors of recurrence and complications after arrhythmias radiofrequency catheter ablation: a nation-wide observational study in Taiwan
por: Lin, Yuan, et al.
Publicado: (2019)

Realities in cost-effectiveness analyses: a study of castration-resistant prostate cancer patients using a medical claims database
por: Kunisawa, Susumu, et al.
Publicado: (2015)

Geriatric Nutritional Risk Index as a Prognostic Marker for Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel
por: Chang, Li-Wen, et al.
Publicado: (2021)

Changes in prostate-specific antigen kinetics during androgen-deprivation therapy as a predictor of response to abiraterone in chemonaïve patients with metastatic castration-resistant prostate cancer
por: Lee, Chung-Lin, et al.
Publicado: (2022)

Utilization Trends of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer in Quebec
por: Hu, Jason, et al.
Publicado: (2022)

Monitoring Patients with Metastatic Hormone-Sensitive and Metastatic Castration-Resistant Prostate Cancer: A Multidisciplinary Consensus Document
por: Lapini, Alberto, et al.
Publicado: (2019)

The prognostic value of the pretreatment lung immune prognostic index in patients with metastatic hormone-sensitive and castration-resistant prostate cancer
por: Wang, Zhipeng, et al.
Publicado: (2023)

First Line Androgen Deprivation Therapy Duration Is Associated with the Efficacy of Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer after Docetaxel
por: Li, Jian-Ri, et al.
Publicado: (2017)

Risk factors for progression to castration-resistant prostate cancer in metastatic prostate cancer patients
por: Lin, Ting-Ting, et al.
Publicado: (2019)

Complementary traditional Chinese medicine therapy improves survival in patients with metastatic prostate cancer
por: Liu, Jui-Ming, et al.
Publicado: (2016)

Real-world evidence of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer using an administrative claims database in Japan
por: Kagawa, Y., et al.
Publicado: (2023)

Serum testosterone levels are positively associated with serum anti-mullerian hormone levels in infertile women
por: Lin, Li-Te, et al.
Publicado: (2021)

AVATAR: A database for genome-wide alternative splicing event detection using large scale ESTs and mRNAs
por: Hsu, Fang Rong, et al.
Publicado: (2005)

Treatment patterns of prostate cancer with bone metastasis in Beijing: A real‐world study using data from an administrative claims database
por: Cheng, Yinchu, et al.
Publicado: (2019)

Health claims databases used for kidney research around the world
por: van Oosten, Manon J M, et al.
Publicado: (2020)

Human Breathomics Database
por: Kuo, Tien-Chueh, et al.
Publicado: (2020)

Retraction to the prognostic value of the pretreatment lung immune prognostic index in patients with metastatic hormone-sensitive and castration-resistant prostate cancer
por: Wang, Zhipeng, et al.
Publicado: (2023)

Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients
por: Vermunt, Marit A. C., et al.
Publicado: (2022)

Visceral Metastasis Predicts Response to New Hormonal Agents in Metastatic Castration-Sensitive Prostate Cancer
por: Yekedüz, Emre, et al.
Publicado: (2023)

Patient-reported outcome labeling claims and measurement approach for metastatic castration-resistant prostate cancer treatments in the United States and European Union
por: Clark, Marci J, et al.
Publicado: (2014)

The Crosstalk of Long Non-Coding RNA and MicroRNA in Castration-Resistant and Neuroendocrine Prostate Cancer: Their Interaction and Clinical Importance
por: Hu, Che-Yuan, et al.
Publicado: (2021)

HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review
por: Bencina, Goran, et al.
Publicado: (2023)

Real-World Database Examining the Association between Sjögren’s Syndrome and Chronic Rhinosinusitis
por: Chang, Geng-He, et al.
Publicado: (2019)

Treatment outcomes with radium-223 in docetaxel-naïve versus docetaxel-treated metastatic castration-resistant prostate cancer patients: Real-world evidence from Taiwan
por: Chiang, Ping-Chia, et al.
Publicado: (2023)

Claims-Based Definition of Death in Japanese Claims Database: Validity and Implications
por: Ooba, Nobuhiro, et al.
Publicado: (2013)

Effectiveness of Deferred Combined Androgen Blockade Therapy Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel
por: Li, Jian-Ri, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_5g2frtgrbiagmpam9snlc3aunf